MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran
pharmaphorum
JUNE 8, 2022
The passport means that LentiGlobin will be reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new innovative licensing and access pathway (ILAP) introduced in 2020, which reduces the review time for a new medicine to 150 days.
52 
Let's personalize your content